[Expression of nuclear factor kappaB and the effect of topical tacrolimus ointment on lesional atopic dermatitis skin].
OBJECTIVE
To investigate the role of nuclear factor kappaB (Rel/NF-kappaB) in pathogenesis of atopic dermatitis(AD) and the effect of topical 0.1%(mass fraction) or 0.03%(mass fraction) tacrolimus ointment on expression of NF-kappaB in lesional AD skin.


METHODS
Immunohistochemistry has been employed to study the expression of NF-kappaB in normal skin and lesional AD skin before and after using topical tacrolimus ointment.


RESULTS
The expressions of NF-kappaBp50 and NF-kappaBp65 were scattering or negative in normal keratinocytes. NF-kappaBp50 was overexpressed on nuclear of basal and suprabasal keratinocytes in 9 cases of AD, NF-kappaBp65 was overexpressed in cytoplasm and perinuclear of basal and suprabasal keratinocytes. After using topical tacrolimus ointment for three weeks , nuclear NF-kappaBp50 expressed on basal and suprabasal keratinocytes were lost and NF-kappaBp50 was expressed sparsely on basal keratinocytes cytoplasm or nuclear. NF-kappaBp65 was expressed sparsely on basal and suprabasal keratinocytes cytoplasm.


CONCLUSIONS
These data suggest that increased NF-kappaB activity may represent the basis of initiation or maintenance of the skin inflammatory response in atopic dermatitis. Topical tacrolimus may directly or indirectly inhibit NF-kappaB nuclear expression in keratinocytes and inhibit skin innate immuno-inflammatory response in atopic dermatitis that related to NF-kappaB.
Xie
Zhi-qiang
ZQ
Department of Dermatology, Peking University First Hospital, Beijing 100034, China.
Liu
Ling-ling
LL
Dou
Xia
X
Wen
Wei-jing
WJ
Wang
Di
D
Zhu
Xue-jun
XJ
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis*; D052002:NF-kappa B p50 Subunit / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051996:Transcription Factor RelA / Q000378:metabolism; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D051996:Transcription Factor RelA; D016559:Tacrolimus